All News

From the Ohio state legislature tackling the “fail first” provision insurances put in place to keep patients with advanced cancer on generic drugs that are less effective to COVID-19 becoming the third leading cause of death in the United States behind cancer, here’s what happened in the cancer landscape this week.

Cancer impacts the entire family, and spouses acting as caregivers are experiencing depression and anxiety, without seeking help.

Patients and their doctors should discuss survivorship issues – such as anxiety and fertility issues – sooner rather than later.

Mortality rate for patients with cancer decreases due to Medicaid expansion for patients with newly diagnosed breast, colorectal and lung cancer.

Dr. Mindy Goldman from the UCSF Hellen Diller Comprehensive Care Center, discusses sexual side effects that cancer survivors face, and offers medication and lifestyle fixes to promote healthy and safe sexual encounters.

Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide contributed to a clinical benefit in 95% of women in the trial and a durable treatment response of 12 months or longer in 25% of women.

Dr. Sally J. York goes over the types of immunotherapy-related side effects, and what patients with lung cancer and their caregivers should look out for.

The FDA granted a priority review to the supplemental biologics license application for the combination of Keytruda and chemotherapy for the firstline treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

Researchers try new drug combination to improve overall survival in patients with recurrent high-grade glioma, but are unsuccessful.

With the second COVID-19 vaccine receiving emergency use authorization by the FDA, patients with cancer undergoing treatment should keep in mind how it may affect their therapy and the potential difference between the two vaccines by Pfizer-BioNTech and Moderna.

This treatment strategy contributed to a median progression-free survival of 13.93 months compared with 9.46 months in those treated with Velcade and dexamethasone.

The decision was based on data that demonstrated sotorasib induced anticancer activity and achieved a positive benefit-risk profile in patients with locally advanced or metastatic non-small cell lung cancer whose disease harbors a KRAS G12C mutation.

An oncology nurse discusses how her peers always provide the best job possible when treating patients with cancer.

A caregiver recognizes the oncology nurse that helped her husband through 9 years of treatment for cancer.

The Moderna COVID-19 Vaccine is delivered similarly to the Pfizer-BioNTech Vaccine, with two doses a month apart. This adds a second vaccine to the arsenal for COVID-19 prevention.

The Food and Drug Administration approved the supplemental new drug application for Iclusig (ponatinib) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.

This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.

Orgovyx is the first oral drug to treat patients with advanced prostate cancer, who were previously treated with intravenous drugs that required clinic visits.

This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.

From a new study showing data that patients with cancer, especially Black patients with cancer, are at a higher risk for COVID-19 than non-cancer patients to NFL punter Rigoberto Sanchez making a speedy recovery after surgery for cancer, here’s what’s happening in the cancer space this week.

An ongoing phase 1/2 was put on hold by the Food and Drug Administration after the death of a patient with pancreatic cancer.

For multiple patients with blood cancers who would normally use Rituxan, the Food and Drug Administration has approved the biosimilar Riabni based off highly similar clinical evidence between the two drugs, potentially lowering costs for patients.

Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.

More than half of the patients with breast cancer who took part in an education-only or exercise-based intervention program remained lymphedema free 18 months following surgery to remove one or more of their lymph nodes.

As treatment delays become more common – especially with the COVID-19 pandemic – delays as much as four weeks can impact the risk for mortality in seven different types of cancer.

Data from the trial that led to the Food and Drug Administration approval demonstrated that Margenza plus chemotherapy reduced the risk of disease progression or death in patients with metastatic HER2-positive breast cancer by 24%, compared with Herceptin plus chemotherapy.

Advancements in the diagnosis and staging of multiple myeloma continue to shape treatment decisions and improve outcomes.

In an interview with CURE®, Dr. Giada Bianchi provides patients an overview of myeloma, including symptoms and risk factors of the disease people should look out for.